Sagimet Biosciences Inc. Series A Common Stock (SGMT) - Net Assets
Based on the latest financial reports, Sagimet Biosciences Inc. Series A Common Stock (SGMT) has net assets worth $102.46 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($107.75 Million) and total liabilities ($5.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Sagimet Biosciences Inc. Series A Common (SGMT) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $102.46 Million |
| % of Total Assets | 95.08% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 49.8 |
Sagimet Biosciences Inc. Series A Common Stock - Net Assets Trend (2019–2025)
This chart illustrates how Sagimet Biosciences Inc. Series A Common Stock's net assets have evolved over time, based on quarterly financial data. See SGMT days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Sagimet Biosciences Inc. Series A Common Stock (2019–2025)
The table below shows the annual net assets of Sagimet Biosciences Inc. Series A Common Stock from 2019 to 2025. For live valuation and market cap data, see SGMT stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $111.38 Million | -28.51% |
| 2024-12-31 | $155.81 Million | +71.09% |
| 2023-12-31 | $91.06 Million | +148.71% |
| 2022-12-31 | $-186.95 Million | -18.13% |
| 2021-12-31 | $-158.26 Million | -16.44% |
| 2020-12-31 | $-135.91 Million | -8.45% |
| 2019-12-31 | $-125.31 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sagimet Biosciences Inc. Series A Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 19079200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | 0.00% |
| Other Comprehensive Income | $120.00K | 0.11% |
| Other Components | $457.61 Million | 410.85% |
| Total Equity | $111.38 Million | 100.00% |
Sagimet Biosciences Inc. Series A Common Stock Competitors by Market Cap
The table below lists competitors of Sagimet Biosciences Inc. Series A Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Sunyes Electronic Manufacturing Holding Co Ltd
SHE:002388
|
$408.78 Million |
|
Aurora Corp
TW:2373
|
$408.78 Million |
|
Orion Engineered Carbons SA
NYSE:OEC
|
$408.82 Million |
|
AbClon Inc
KQ:174900
|
$408.87 Million |
|
Costamare Bulkers Holdings Limited
NYSE:CMDB
|
$408.65 Million |
|
Anhui Sunhere Pharmaceutical Excipients Co Ltd
SHE:300452
|
$408.61 Million |
|
Key Ware Electronics Co Ltd
TWO:5498
|
$408.60 Million |
|
Wuhan Nusun Landscape Co Ltd
SHE:300536
|
$408.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sagimet Biosciences Inc. Series A Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 155,805,000 to 111,381,000, a change of -44,424,000 (-28.5%).
- Net loss of 51,038,000 reduced equity.
- Other comprehensive income decreased equity by 110,000.
- Other factors increased equity by 6,724,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-51.04 Million | -45.82% |
| Other Comprehensive Income | $-110.00K | -0.1% |
| Other Changes | $6.72 Million | +6.04% |
| Total Change | $- | -28.51% |
Book Value vs Market Value Analysis
This analysis compares Sagimet Biosciences Inc. Series A Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.94x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-5.65 | $6.68 | x |
| 2020-12-31 | $-6.13 | $6.68 | x |
| 2021-12-31 | $-7.14 | $6.68 | x |
| 2022-12-31 | $-8.43 | $6.68 | x |
| 2023-12-31 | $5.01 | $6.68 | x |
| 2024-12-31 | $4.97 | $6.68 | x |
| 2025-12-31 | $3.44 | $6.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sagimet Biosciences Inc. Series A Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -45.82%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.05x
- Recent ROE (-45.82%) is below the historical average (-15.10%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.73 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $2.22 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.62 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.80 Million |
| 2023 | -30.61% | -1393.80% | 0.02x | 1.06x | $-36.98 Million |
| 2024 | -29.25% | 0.00% | 0.00x | 1.03x | $-61.15 Million |
| 2025 | -45.82% | 0.00% | 0.00x | 1.05x | $-62.18 Million |
Industry Comparison
This section compares Sagimet Biosciences Inc. Series A Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $27,896,581
- Average return on equity (ROE) among peers: -64.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sagimet Biosciences Inc. Series A Common Stock (SGMT) | $102.46 Million | 0.00% | 0.05x | $408.71 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $85.57 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $328.21 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $35.44 Million | -26.32% | 0.18x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-1.46 Million | 0.00% | 0.00x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.90 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $67.16 Million | -67.08% | 0.33x | $3.66 Billion |
About Sagimet Biosciences Inc. Series A Common Stock
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfun… Read more